Basit öğe kaydını göster

dc.contributor.authorŞahan C.
dc.contributor.authorCengiz K.
dc.date.accessioned2020-06-21T09:23:28Z
dc.date.available2020-06-21T09:23:28Z
dc.date.issued2005
dc.identifier.issn1300-2996
dc.identifier.urihttps://hdl.handle.net/20.500.12712/3562
dc.description.abstractAntiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a combination of arterial or venous thrombosis and recurrent fetal loss, accompanied by elevated titers of antiphospholipid antibodies (aPL). Two forms have bee described: the "primary syndrome" where there is no evidence of an underlying disease, and the "secondary" syndrome, mainly in the setting of systemic lupus eryhematosus. In 1998; an international panel of experts met in Sapporo to establish the classification criteria for definite antiphospholipid syndrome. Two assays are available to demonstrate the presence of antiphospholipid antibodies in plasma of patients: ELISA for the detection of anticardiolipin antibodies and coagulation assays for the detection of the lupus anticoagulants. Treatment decisions fall into four main areas. Prophylaxis, prevention, treatment of acute thrombosis, and management of pregnancy in association with antiphospholipid antibodies.en_US
dc.language.isoturen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnticardiolipin antibodyen_US
dc.subjectAntifosfolipid syndromeen_US
dc.subjectLupus anticoagulanen_US
dc.titlePrimary anti-phospholipid syndromeen_US
dc.title.alternativePrimer antifosfolipid sendromuen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume22en_US
dc.identifier.issue2en_US
dc.identifier.startpage100en_US
dc.identifier.endpage111en_US
dc.relation.journalOndokuz Mayis Universitesi Tip Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster